AHMEDABAD | MUMBAI | RAJKOT - In a regulatory update submitted to the Indian Stock Exchanges, Ahmedabad headquartered Cadila Healthcare Ltd (Dr Pankaj Patel lead Zydus Cadila Group) said of having got nod from USFDA (US Food & Drugs Administration) to market medicines to cure cardiac problems and skin-treatment.
In a press-release as submitted by the company to the Indian Bourses titled - "Zydus receives final approvals from the USFDA for Isosorbide Dinitrate Tablets and Desonide Cream," it further read that, Zydus Cadila has received the final approval from the USFDA to market lsosorbide Dinitrate Tablets USP (US RLD — Isordil Tablet) in the strengths of 5mg, 10 mg, 20 mg, 30 mg and 40 mg.
The drug is used to prevent attacks of chest pain (angina).
lt dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump.
The group also received the final approval for Desonide Cream (US RLD — Desonide Cream), 0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema,dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types of conditions.
It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has 278 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003—04.
The group employs over 24,000 people worldwide and is dedicated to creating healthier communities globally.
Zydus aspires to be a research-based pharmaceutical company by 2020.
FOLLOW US ON :-
- BLOG : http://datelinegujarat.blogspot.com/
- FACEBOOK : https://facebook.com/dateline.gujarat
- GOOGLE+ : https://plus.google.com/110800330482982580799
- INSTAGRAM : https://www.instagram.com/datelinegujarat/
- LINKEDIN : https://in.linkedin.com/in/dateline-gujarat-7681885a
- TELEGRAM : https://t.me/DATELINEGUJARATDOTCOM
- TWITTER : https://twitter.com/DatelineGujarat
- YOUTUBE : https://www.youtube.com/user/DatelineGujarat
- WEBSITE (URL) : https://datelinegujarat.com/
No comments:
Post a Comment